AAV / Gene Therapy CDMOs — Ranked by Signal Score · 2026
· updated as new inspection, certificate, and trial data enters the platform
55
CDMOs tracked
55
Fully scored
17
With FDA records
52
FDA inspections
196
EMA/MHRA GMP certs
2
Warning letters
Shortlist AAV / gene therapy CDMOs with Signal
CDMO Signal is an independent sourcing platform for comparing and shortlisting AAV and gene therapy CDMOs before an RFI. This page is the entry point — the ranked table below is derived from FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals. Use it to narrow the field, then evaluate whether each shortlisted supplier's public evidence supports your serotype, scale, and analytics requirements before contacting them.
- Compare AAV and gene therapy CDMOs side-by-side on FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals — every number traceable to primary sources.
- Filter by regulatory jurisdiction, clean-inspection posture, and clinical-program breadth to your program's shortlisting criteria.
- Shortlist Use the ranked results to build your shortlist, then open each profile to review the underlying evidence before contacting suppliers. Follow up with the shortlisted CDMOs to evaluate whether their public evidence — and their direct answers to your RFI — support your serotype, scale, and analytics requirements.
On CDMO Signal's composite Signal Score, Takeda, Thermo Fisher Scientific, and AGC Biologics lead the AAV / gene therapy CDMO rankings. Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. AAV CDMO selection turns on serotype experience, suspension vs adherent platform maturity, full/empty capsid analytics, and defensible regulatory posture. Rankings are recomputed daily. Full methodology at cdmosignal.com/methodology.
Adeno-associated virus (AAV) is the dominant delivery platform for in vivo gene therapy, from rare-disease programs to larger systemic indications. Rising demand has pushed CDMOs to scale suspension processes and tighten full/empty capsid analytics.
Selecting an AAV CDMO hinges on serotype experience, suspension vs adherent platform, full/empty capsid separation, and a proven regulatory record. The rankings below score each manufacturer on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 20 NAI (no action), 30 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (50), United States (46), Denmark (35), Germany (22), Italy (15).
Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
TK
Takeda
Boston, MA · Zurich, CH
|
81.9 | 99.6 | 4 insp · 18 GMP | — | 100 programs |
| 2 |
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
|
81.0 | 100.0 | 6 insp · 10 GMP | Available | 2 programs |
| 3 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
78.6 | 100.0 | 2 insp · 23 GMP | Available | 2 programs |
| 4 |
OX
Oxford Biomedica
Oxford, United Kingdom
|
76.2 | 100.0 | 0 insp · 13 GMP | Available | 7 programs |
| 5 |
Lonza
Basel, Switzerland
|
76.0 | 95.7 | 2 insp · 8 GMP | — | 1 programs |
| 6 |
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
|
75.2 | 100.0 | 1 insp · 0 GMP | — | 1 programs |
| 7 |
RT
ReiThera
Rome, IT
|
71.1 | 100.0 | 0 insp · 4 GMP | — | 1 programs |
| 8 |
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
90.9 | 98.3 | 8 insp · 11 GMP | Limited | 0 programs |
| 9 |
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
|
88.0 | 100.0 | 0 insp · 3 GMP | — | 0 programs |
| 10 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 11 |
FD
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
|
84.8 | 100.0 | 0 insp · 23 GMP | 0 programs | |
| 12 |
KB
KBI Biopharma
Durham, NC · Boulder, CO
|
84.4 | 99.1 | 1 insp · 1 GMP | Limited | 0 programs |
| 13 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 14 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
82.9 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 15 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
81.6 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 16 |
DH
Danaher (CGT Portfolio)
Washington, DC
|
81.5 | — | — | — | 0 programs |
| 17 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 18 |
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
|
80.2 | 97.1 | 4 insp · 8 GMP | — | 0 programs |
| 19 |
OB
OmniaBio
Hamilton, ON
|
79.5 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 20 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 21 |
UM
MassBiologics
Boston, MA
|
79.0 | 97.2 | 1 insp · 0 GMP | — | 0 programs |
| 22 |
AA
Ascend Advanced Therapies
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 23 |
NG
NecstGen
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 24 |
ET
Exothera
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 25 |
PG
ProBioGen
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | — | 0 programs |
| 26 |
CE
Celonic
Basel, Switzerland
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 27 |
XP
eXmoor Pharma
Bristol, United Kingdom
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 28 |
AD
Advent Bioservices
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 29 |
BV
Biovian
Turku, Finland
|
78.0 | 99.8 | 1 insp · 4 GMP | — | 0 programs |
| 30 |
AG2
August Bioservices
San Carlos, CA
|
77.5 | 98.7 | 1 insp · 0 GMP | — | 0 programs |
| 31 |
VG
Viralgen Vector Core
San Sebastián, Spain
|
76.8 | 100.0 | 0 insp · 4 GMP | Available | 0 programs |
| 32 |
CG
Cytiva (Mfg Services)
Marlborough, MA · Uppsala, SE
|
74.0 | — | — | — | 0 programs |
| 33 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
|
73.1 | 74.9 | 12 insp · 37 GMP | — | 0 programs |
| 34 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
73.1 | 74.9 | 1 insp · 0 GMP | Available | 0 programs |
| 35 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
73.0 | 95.7 | 1 insp · 0 GMP | Limited | 0 programs |
| 36 |
VE
Vigene Biosciences
Rockville, MD
|
72.5 | — | — | — | 0 programs |
| 37 |
GZ
Genezen
Indianapolis, IN · Lexington, MA
|
71.5 | 85.8 | 3 insp · 0 GMP | Available | 0 programs |
| 38 |
EM
Emergent BioSolutions (CGT)
Baltimore, MD
|
71.0 | — | — | — | 4 programs |
| 39 |
IU
Indiana University Vector Production Facility
Indianapolis, IN
|
66.3 | — | — | — | 49 programs |
| 40 |
AN
Andelyn Biosciences
Columbus, OH
|
63.0 | — | — | Available | 0 programs |
| 41 |
RA
Recipharm Advanced Bio
Stockholm, Sweden
|
63.0 | — | — | — | 0 programs |
| 42 |
AB
Asklepios BioPharmaceutical (AskBio)
Research Triangle, NC · San Sebastian, ES
|
61.8 | — | — | — | 10 programs |
| 43 |
FB
Forge Biologics
Columbus, OH
|
61.2 | — | — | 3 programs | |
| 44 |
MA
Matica Biotechnology
College Station, TX
|
59.0 | — | — | Available | 0 programs |
| 45 |
VB
VintaBio
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 46 |
MS
Made Scientific
Princeton, NJ
|
59.0 | — | — | — | 0 programs |
| 47 |
WB
Waisman Biomanufacturing
Madison, WI
|
59.0 | — | — | — | 0 programs |
| 48 |
EB
ElevateBio BaseCamp
Waltham, MA
|
59.0 | — | — | — | 0 programs |
| 49 |
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
|
59.0 | — | — | — | 0 programs |
| 50 |
VM
Vector BioMed
Cambridge, MA
|
59.0 | — | — | — | 0 programs |
| 51 |
AM
Anemocyte
Gerenzano, IT
|
59.0 | — | — | — | 0 programs |
| 52 |
HX
Helixmith
Seoul, KR
|
59.0 | — | — | — | 0 programs |
| 53 |
Vantage Vector (Demo)
Gaithersburg, MD
|
59.0 | — | — | Available | 0 programs |
| 54 |
UB
uBriGene Biosciences
Shanghai, CN · Boston, MA
|
56.5 | — | — | — | 0 programs |
| 55 |
CV
CEVEC Pharmaceuticals
Cologne, Germany
|
56.5 | — | — | — | 0 programs |
What to evaluate in a AAV / Gene Therapy CDMO
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Suspension vs adherent AAV — which platforms do CDMOs use?
AAV manufacturing uses two upstream platforms: adherent (HEK293 on flasks or fixed-bed bioreactors) and suspension (HEK293-based cells in stirred-tank bioreactors). Suspension scales more cleanly for commercial volumes and is the industry direction, but many CDMOs still support adherent for smaller-batch and rare-disease programs. Larger diversified viral vector CDMOs typically run both. The specific platform a CDMO uses for a given serotype is an important early diligence question; ask about validated bioreactor scale for the target serotype and the productivity (vg/L) achieved.
Full/empty capsid capabilities — how AAV CDMOs differ
Full/empty capsid ratio is the AAV analytics variable that most drives potency and safety. CDMOs differ in the maturity of their downstream separation — analytical ultracentrifugation (AUC), anion-exchange chromatography, cesium chloride gradient — and in operator experience with each technique. Signal Score does not yet track per-CDMO capsid separation platforms directly, so sponsors should raise the question during vendor selection. Individual CDMO profile pages capture press-monitored capacity expansions that often flag downstream investment; the methodology page outlines what is and isn't in scope.
Which AAV CDMOs handle commercial-scale supply?
Commercial-scale AAV manufacturing is a rapidly maturing segment. The commercial-scale AAV filter surfaces CDMOs with top-quartile Signal Score or broad ClinicalTrials.gov footprint. Commercial AAV has historically been dominated by pure-play viral vector specialists, but larger diversified CDMOs have added capacity aggressively over the last three years. Sponsors weighing commercial supply should verify not just capacity headroom but demonstrated tech transfer of full/empty capsid analytics and consistency across scale-up runs — this is where late-stage programs most often stumble.
How CDMO Signal computes the AAV ranking
The AAV Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications (NAI, VAI, OAI), Warning Letter history, and EMA/MHRA GMP certificate density. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint matched to each CDMO. Financial Stability (20%) draws on SEC filings and parent-company signals. Capacity Intelligence (20%) tracks monitored trade press for facility expansions and capacity additions. For AAV specifically, Quality Compliance and Capacity Intelligence disproportionately signal — this is a modality where facility investment and regulatory posture directly enable or block commercial supply. Full weightings at cdmosignal.com/methodology.
Serotype experience — AAV2, AAV5, AAV6, AAV8, AAV9 across CDMOs
AAV serotypes have distinct tropism and manufacturing characteristics. AAV2 is the historical reference serotype with the deepest CDMO experience base but modest yields. AAV5 and AAV8 are common for liver and neuromuscular indications. AAV9 crosses the blood-brain barrier and dominates CNS gene therapy programs but presents higher immunogenicity considerations. AAV6 is used in ex vivo genome editing workflows. Most CDMOs specialize in a subset — pure-play viral vector CDMOs typically have qualified processes across 3-5 serotypes; larger diversified CDMOs may cover 6+. Sponsors should ask for validated productivity (vg/L or vg/cell) at the target serotype specifically, since yields vary 3-5× across serotypes on the same platform. The individual CDMO profile pages capture qualified serotypes where disclosed.
Which AAV CDMOs manufacture FDA-approved commercial products?
Commercial AAV manufacturing is a very narrow field. Approved AAV gene therapies to date include Luxturna (Spark, AAV2), Zolgensma (Novartis, AAV9), Hemgenix (CSL, AAV5), Roctavian (BioMarin, AAV5), Elevidys (Sarepta, AAVrh74), and Casgevy (uses CRISPR-Cas9 with AAV6 for delivery). Manufacturing has historically been done at the innovator or through a small set of specialized CDMOs including Oxford Biomedica, Catalent, Thermo Fisher, and Charles River. This is the highest-bar quality signal — sponsors targeting commercial supply should treat commercial AAV track record as a hard qualifying criterion, and verify not just "has capacity" but "has delivered validated commercial lots." The commercial-scale AAV filter surfaces CDMOs with the strongest current signal.
Rare disease AAV — batch size, dose, and cost considerations
Rare disease AAV programs face a distinctive economics: extremely high per-patient dose (often 10^13-10^14 vg/kg for systemic delivery, 10^15 vg total for a 100kg adult) combined with small patient counts (hundreds to low thousands globally). This flips the standard commercial-scale calculus — you need enough capacity for high-dose batches but may only run a few campaigns per year. Sponsors should verify the CDMO's largest validated batch is sized appropriately (typically 500L-2000L suspension for systemic dosing), and separately confirm their small-batch adherent option remains available for lower-dose pediatric or CNS-injected programs. Cost per dose at rare disease scale often runs six figures at the CDMO level alone; that pricing dynamic is what makes tech transfer risk especially costly to correct mid-program.
How to structure an AAV CDMO RFP — a 6-step buyer framework
For sponsors running competitive AAV CDMO selection: 1. Serotype-specific yield disclosure — ask each CDMO for their validated productivity in vg/cell or vg/L for your target serotype, not their platform average. 2. Full/empty separation approach — AUC, anion-exchange, or CsCl, and demonstrated DAR consistency across scale-up runs. 3. Analytics package — potency assays (typically transduction-based cell assays), residual DNA specs, capsid identity confirmation. 4. Regulatory posture — FDA inspection classifications specifically on the facility slated for your program (see ranked table above and each CDMO profile). 5. Timeline realism — first-in-human material typically 12-18 months from tech transfer; commercial supply 3-5 year engagement with tech-transfer costs weighted heavily to year one. 6. Capacity headroom — verify the CDMO isn't slot-constrained by other programs in your target campaign window. Comparability data between the CDMO's development runs and their validated GMP process is what most sponsors underestimate.
AAV / Gene Therapy CDMOs — Frequently Asked Questions
Who are the top AAV / Gene Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked AAV / Gene Therapy CDMOs include Takeda, Thermo Fisher Scientific, AGC Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many AAV / Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 17 AAV / Gene Therapy CDMOs with FDA inspection records and 196 EMA/MHRA GMP certificates across the group.
What should I look for in an AAV CDMO?
Look for serotype experience, a scalable suspension platform, strong full/empty capsid analytics, and a clean FDA and EMA/MHRA record. Match validated bioreactor scale to your dose and indication.
What's the difference between AAV and lentiviral CDMOs?
AAV is non-integrating and produced at higher volumes for in vivo gene therapy. Lentivirus integrates into the genome, is made under BSL-2 with RCL testing, and is used mainly for ex vivo cell engineering like CAR-T.
Related modalities